2024-06-12 23:30 (수)
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
  • PR Newswire
  • 승인 2024.05.07 14:27
  • 댓글 0
이 기사를 공유합니다

YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4. This research was conducted through a collaborative effort with Genece Health Inc., a strategic partner based in San Diego.

Poster Presentation Details:

Title: Non-invasive colorectal cancer detection using multimodal deep learning ensemble classifier.

  • Date and Time: Saturday, June 1, 2024 9:00 AM - 12:00 PM CDT
  • Format: Poster Presentation
  • Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
  • Poster Board Number: 211
  • Abstract Number: 3066

[About GC Genome]

GC Genome is a leading diagnostics company that aims to connect the care and cure to the world by offering genetic diagnosis services for Oncology, Pre&Neonatal, Rare Diseases, and Health Check-ups and suggesting personalized treatment for longer and healthier lives. Established in 2013 as a GC company, GC Genome operates a CAP-accredited laboratory and places the utmost emphasis on R&D. With steadfast partnerships established worldwide, GC Genome has shown impressive growth momentum, continually expanding our testing capacities.

[About Genece Health]
Genece leverages a proprietary liquid biopsy and deep-learning AI technology for early cancer detection. The Company was founded in 2022 through a strategic partnership with GC Genome, the genomics arm of GC Corporation, a leading life sciences company in South Korea. Genece focuses on the acute need for targeted screening and detection tools to support decision-making when a mass or lump is detected through imaging, empowering physicians to make informed decisions and improve care. The Company's initial applications include high-mortality and women's health cancers.

Investor/Media Contact 
GC Corp. Contacts (Media)

Sohee Kim
shkim20@gccorp.com

Yelin Jun
yelin@gccorp.com

Rachel Kim
rachel.kim@gccorp.com

PR Newswire

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.